Perrigo meets demand
This article was originally published in The Tan Sheet
Executive Summary
The private labeler increases its manufacturing capacity by 10 percent and its production of OTC tablets by 3 billion a year with the addition of a $25 million, 62,000-square foot facility in Allegan, Mich. The company announces the 18-month construction project Oct. 15, a month after adding a 160,000 square-foot manufacturing facility in its $44 million acquisition of JB Laboratories in nearby Holland, Mich., and a week after acquiring Mexican store-brand manufacturer Laboratorios Diba for $25 million (1"The Tan Sheet" Oct. 13, 2008, p. 3). Spokesman Art Shannon says Perrigo planned the expansion before buying JB and Diba, and it may need more manufacturing capacity. Demand for Perrigo's products "is increasing across the board," he says. "We make 30 billion tablets [annually] and it keeps growing with all the new products that we have. We just need additional manufacturing capacity.
You may also be interested in...
Perrigo Bets On Mexican Private Label Growth With Laboratorios Diba Buy
Perrigo is betting the Mexican store-brand market will grow the way private label did in the U.S. 20 years ago, with its $25 million acquisition of Laboratorios Diba
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.